Mainstay Medical is developing ReActiv8, an implantable peripheral nerve stimulator system leveraging a novel neurorehabilitation therapy approach to treat chronic, non-specific, low back pain. Chronic low back pain is a major unmet medical problem afflicting millions of people world-wide each year, where conventional therapies have limited effectiveness for the majority of patients. Both the Capital Fund and the Crossover Fund have invested in Mainstay.
Capital & Crossover
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.